Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by US Oncology Research.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
ImClone LLC
Sanofi
Information provided by:
US Oncology Research
ClinicalTrials.gov Identifier:
NCT00517829
First received: August 15, 2007
Last updated: April 22, 2010
Last verified: April 2010
  Purpose

The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.


Condition Intervention Phase
Metastatic Gastric or GEJ Cancer
Drug: Docetaxel + oxaliplatin
Drug: Docetaxel + oxaliplatin + cetuximab
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Docetaxel Plus Oxaliplatin (DOCOX) With Cetuximab in Patients With Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma

Resource links provided by NLM:


Further study details as provided by US Oncology Research:

Primary Outcome Measures:
  • To determine the progression-free survival produced by the combination of docetaxel (Taxotere) + oxaliplatin (Eloxatin) + cetuximab (ERBITUX) [ Time Frame: Treatment will continue until disease progression or intolerable toxicity ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: July 2007
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Taxotere as an intravenous (IV) infusion over 1 hour, followed by Eloxatin IV over 2 hours
Drug: Docetaxel + oxaliplatin
Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour, followed by Eloxatin 130 mg/m2 IV over 2 hours
Other Names:
  • Taxotere (docetaxel)
  • Eloxatin (oxaliplatin)
Active Comparator: 2
Taxotere 60 mg/m2 as an IV infusion over 1 ho ur, followed by Eloxatin 130 mg/m2 IV over 2 hours, followed by ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
Drug: Docetaxel + oxaliplatin + cetuximab
Taxotere 60 mg/m2 as an IV infusion over 1 hour, followed by Eloxatin 130 mg/m2 IV over 2 hours, followed by ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
Other Names:
  • Taxotere(docetaxel)
  • Eloxatin (oxaliplatin)
  • ERBITUX (cetuximab)

Detailed Description:

This is a Phase II, open- label, randomized, noncomparative study. Patients will be stratified at randomization by ECOG PS. There is no intent to have equal numbers of patients for each PS (ie, 0, 1, and 2), but rather stratification will be conducted to ensure that the 2 treatment arms are well-balanced for ECOG PS.

Patients will be randomly assigned to either Arm 1 - Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour, followed by Eloxatin 130 mg/m2 IV over 2 hours or Arm 2 - Taxotere 60 mg/m2 as an IV infusion over 1 ho ur, followed by Eloxatin 130mg/m2 IV over 2 hours, followed by ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes. Taxotere and Eloxatin will be given on Day 1 of each 21-day cycle; ERBITUX is given on Days 1, 8, and 15 of each cycle.

Treatment will continue until disease progression or intolerable toxicity. Patients who achieve a CR will receive an additional 2 cycles of treatment. Patients will be limited to 24 months of participation, counted from the date of the first dose of study drug.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has histologically confirmed Stage IV adenocarcinoma of the GEJ/stomach

Note: Adjuvant radiation plus treatment with 5-FU and leucovorin is permitted, but not required.

  • Patients must have measurable disease
  • Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2
  • Patient is greater than 18 years of age
  • If present, any pre-existing (current) peripheral neuropathy must be ≤ Grade 1
  • Patient's laboratory values must fall within the limits set forth in section 4.2 of the protocol
  • Patient has a negative serum pregnancy test within 7 days prior to registration (female patients of childbearing potential)
  • If fertile, patient (male or female) has agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a 2 month period thereafter
  • Patient (or guardian) has signed a Patient Informed Consent Form
  • Patient (or guardian) has signed a Patient Authorization Form

Exclusion Criteria:

  • Patient has any metastatic disease other than that defined in section 4.2 (criterion #1)
  • Patient has had prior treatment that included anything other than adjuvant radiation plus treatment with 5-FU and leucovorin. Prior treatment must have been completed > 6 months prior to registration in current study. No other prior regimens are allowed.

Note: Adjuvant radiation plus treatment with 5-FU and leucovorin is permitted, but not required.

  • If present, any peripheral neuropathy is > Grade 1
  • Patient has a known hypersensitivity to Taxotere (or any drug formulated with Polysorbate-80), or Eloxatin
  • Has had a prior severe infusion reaction (Grade 4) to a monoclonal antibody
  • Has received prior therapy, at any time, which specifically and directly targets the EGFR pathway
  • Patient is receiving concurrent immunotherapy or any other concurrent treatment for their cancer
  • Has had prior stem cell or bone marrow transplant or any organ transplant with the exception of corneal transplant or cadaver bone graft
  • Has a significant history of uncontrolled cardiac disease; ie, uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, or cardiomyopathy with decreased ejection fraction (LVEF<50%)
  • Has evidence of CNS involvement (CNS imaging is not required for study enrollment unless clinically suspected CNS disease is present.)
  • Patient has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
  • Patient is known to be HIV positive or have a history of hepatitis B or C
  • Patient has a history of other malignancy within the last 5 years (except for squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix , or superficial transitional cell carcinoma of the bladder), which could affect the diagnosis or assessment of current condition.
  • Patient is a pregnant or lactating woman
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00517829

  Show 47 Study Locations
Sponsors and Collaborators
US Oncology Research
ImClone LLC
Sanofi
Investigators
Principal Investigator: Donald A Richards, MD US Oncology Research
  More Information

No publications provided by US Oncology Research

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Debra Bailey, RN, US Oncology Research
ClinicalTrials.gov Identifier: NCT00517829     History of Changes
Other Study ID Numbers: 06063
Study First Received: August 15, 2007
Last Updated: April 22, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Oxaliplatin
Docetaxel
Cetuximab
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 15, 2014